555 related articles for article (PubMed ID: 10881018)
1. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.
Thalmann GN; Sikes RA; Wu TT; Degeorges A; Chang SM; Ozen M; Pathak S; Chung LW
Prostate; 2000 Jul; 44(2):91-103 Jul 1;44(2). PubMed ID: 10881018
[TBL] [Abstract][Full Text] [Related]
2. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.
Wu HC; Hsieh JT; Gleave ME; Brown NM; Pathak S; Chung LW
Int J Cancer; 1994 May; 57(3):406-12. PubMed ID: 8169003
[TBL] [Abstract][Full Text] [Related]
3. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
Thalmann GN; Anezinis PE; Chang SM; Zhau HE; Kim EE; Hopwood VL; Pathak S; von Eschenbach AC; Chung LW
Cancer Res; 1994 May; 54(10):2577-81. PubMed ID: 8168083
[TBL] [Abstract][Full Text] [Related]
4. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.
Wu TT; Sikes RA; Cui Q; Thalmann GN; Kao C; Murphy CF; Yang H; Zhau HE; Balian G; Chung LW
Int J Cancer; 1998 Sep; 77(6):887-94. PubMed ID: 9714059
[TBL] [Abstract][Full Text] [Related]
5. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
6. Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells.
Thalmann GN; Rhee H; Sikes RA; Pathak S; Multani A; Zhau HE; Marshall FF; Chung LW
Eur Urol; 2010 Jul; 58(1):162-71. PubMed ID: 19747763
[TBL] [Abstract][Full Text] [Related]
7. Human prostate cancer progression models and therapeutic intervention.
Chung LW; Kao C; Sikes RA; Zhau HE
Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
[TBL] [Abstract][Full Text] [Related]
8. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice.
Pettaway CA; Pathak S; Greene G; Ramirez E; Wilson MR; Killion JJ; Fidler IJ
Clin Cancer Res; 1996 Sep; 2(9):1627-36. PubMed ID: 9816342
[TBL] [Abstract][Full Text] [Related]
9. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
[TBL] [Abstract][Full Text] [Related]
10. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
11. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model.
Igawa T; Lin FF; Lee MS; Karan D; Batra SK; Lin MF
Prostate; 2002 Mar; 50(4):222-35. PubMed ID: 11870800
[TBL] [Abstract][Full Text] [Related]
12. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
[TBL] [Abstract][Full Text] [Related]
13. Androgen-repressed phenotype in human prostate cancer.
Zhau HY; Chang SM; Chen BQ; Wang Y; Zhang H; Kao C; Sang QA; Pathak SJ; Chung LW
Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15152-7. PubMed ID: 8986779
[TBL] [Abstract][Full Text] [Related]
14. Establishment of two human prostate cancer cell lines derived from a single bone metastasis.
Navone NM; Olive M; Ozen M; Davis R; Troncoso P; Tu SM; Johnston D; Pollack A; Pathak S; von Eschenbach AC; Logothetis CJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2493-500. PubMed ID: 9815652
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
16. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
17. Elevated expression of FGF-2 does not cause prostate cancer progression in LNCaP cells.
Russell PJ; Bennett S; Joshua A; Yu Y; Downing SR; Hill MA; Kingsley EA; Mason RS; Berry J
Prostate; 1999 Jun; 40(1):1-13. PubMed ID: 10344718
[TBL] [Abstract][Full Text] [Related]
18. Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors.
Leung SY; Jackson J; Miyake H; Burt H; Gleave ME
Prostate; 2000 Jul; 44(2):156-63. PubMed ID: 10881025
[TBL] [Abstract][Full Text] [Related]
19. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.
Hsieh JT; Wu HC; Gleave ME; von Eschenbach AC; Chung LW
Cancer Res; 1993 Jun; 53(12):2852-7. PubMed ID: 7684949
[TBL] [Abstract][Full Text] [Related]
20. Molecular alterations associated with LNCaP cell progression to androgen independence.
Shi XB; Ma AH; Tepper CG; Xia L; Gregg JP; Gandour-Edwards R; Mack PC; Kung HJ; deVere White RW
Prostate; 2004 Aug; 60(3):257-71. PubMed ID: 15176055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]